Kathleen D. Scott
Director · Dermata Therapeutics, Inc.
- 2024
- Jun 16, 2026
- 5
Summary
Latest filing:
Kathleen D. Scott is Director of Dermata Therapeutics, Inc. (DRMA). 5 SEC Form 4 filings on record going back to 2024, most recently on 16 June 2026. Most recent open-market trade: sold $13 of DRMA on 16 June 2026. Lifetime open-market sales: $388K.
Recent transactions
5The latest 5 SEC Form 4 transactions reported by Kathleen D. Scott.
Trading pattern
InsiderAlpha's records for Kathleen D. Scott go back to 2024: 5 primary Form 4 filings, an average of 1.7 per year. 3 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Kathleen D. Scott files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Justin Chakma - $1.48M in SPRY purchases and sales in the last 12 months
- Eric Karas - $250K in SPRY purchases and sales in the last 12 months
- Brian Dorsey - $190K in SPRY purchases and sales in the last 12 months
- Alexander A. Fitzpatrick - $34K in SPRY purchases and sales in the last 12 months
- Munera Maria E. Bedoya-Toro - $1K in DRMA purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Kathleen D. Scott?
Kathleen D. Scott is a corporate insider, tracked as Director of Dermata Therapeutics, Inc. (DRMA). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Kathleen D. Scott last file a Form 4?
The most recent primary Form 4 on record is dated 16 June 2026, one of 5 filings going back to 2024.
Has Kathleen D. Scott been buying or selling stock?
Recorded transactions: 0 open-market purchases and 3 open-market sales ($388K) across all tracked filings.